00570 TRAD CHI MED
- 4.290
- -0.010-0.23%
TRAD CHI MED News
中國中藥：2023年年報
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
China Traditional Chinese Medicine Posts 94% Profit Growth in 2023
China Traditional Chinese Medicine Holdings Co (HKG:0570) recorded a 93.6% rise in its net profit to 1.40 billion yuan in 2023, against 720.96 million yuan a year ago, according to a Thursday filing w
China Traditional Chinese Medicine announces 2023 annual results, profit attributable to shareholders of 1,285 billion yuan, an increase of 68.11% year-on-year
China Traditional Chinese Medicine (00570) announced annual results for the year ended December 31, 2023. The group achieved a turnover of 18.122 billion yuan (RMB, same below) during the period, an increase of 26.69% over the previous year; profit attributable to shareholders was 1,285 billion yuan, an increase of 68.11% over the previous year; and basic profit per share was 25.52 points.
China Traditional Chinese Medicine (00570.HK)'s annual net profit of 1,396 billion yuan increased 93.6% year-on-year
Gelonghui, March 21, 丨 China Traditional Chinese Medicine (00570.HK) announced that for the year ended December 31, 2023, the company's turnover was RMB 18.1 billion, up 26.7% from the same period in 2022; net profit was RMB 1,396 billion, up 93.6% from the same period in 2022. No dividend payments were recommended for the year.
TRAD CHI MED: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Chinese Traditional Chinese Medicine (00570.HK): Cheng Xueren resigns as president (i.e. general manager)
Gelonghui, March 21 | Chinese Traditional Chinese Medicine (00570.HK) announced that the board of directors has received written resignation reports from Cheng Xueren and Yang Wenming. Since they have reached the legal retirement age, Cheng Xueren applied to resign as the company's president (i.e. general manager) and be reassigned from the executive director and managing director to non-executive directors; Yang Wenming applied to resign as the company's vice president, and was transferred from the executive director to a non-executive director.
China Traditional Chinese Medicine (00570.HK) plans to hold a board meeting on March 21 to approve annual results
Gelonghui, March 11, 丨 China Traditional Chinese Medicine (00570.HK) announced that the company will hold a board meeting on March 21, 2024 (Thursday) to consider and approve the final results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any).
TRAD CHI MED: DATE OF BOARD MEETING
China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Stocks Shoot Up 47% But Its P/E Still Looks Reasonable
China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) shareholders would be excited to see that the share price has had a great month, posting a 47% gain and recovering from prior weakness
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer
Shares of China Traditional Chinese Medicine Holdings (HKG:0570) finished some 24% higher today, Feb. 22, a day after parent Sinopharm Group (HKG:1099) said it intends to privatize the maker of old-wo
Beishui Trends | With a net purchase of 4.777 billion yuan, central state-owned enterprises are still favored, China's traditional Chinese medicine (00570) resumed trading and was sold off by domestic investors
On February 22, in the Hong Kong stock market, Beishui had a net purchase of HK$4.777 billion, of which the Hong Kong Stock Connect (Shanghai) transaction made a net purchase of HK$2,214 billion and the Hong Kong Stock Connect (Shenzhen) transaction made a net purchase of HK$2,563 billion.
Hong Kong Stocks Hover Near Two-Month Highs Amid Mixed Corporate Earnings
Hong Kong stocks hovered near a two-month high on Thursday, as investors took in mixed corporate earnings, with Asia-focused HSBC (HKG:0005) disappointing the market, while travel platform operator Tr
Changes in Hong Kong stocks | China Traditional Chinese Medicine (00570) resumed trading with more than 24% and received a 34.11% privatization premium from Sinopharm
The Zhitong Finance App learned that China's traditional Chinese medicine (00570) resumed trading by more than 24%. As of press release, it had risen 24.49% to HK$4.27, with a turnover of HK$125 million. According to the news, China Traditional Chinese Medicine announced that Sinopharm Group proposed to privatize Chinese medicines at a cash price of HK$4.6 per share through planned arrangements. Sinopharm's price is a 34.11% premium over the latest closing price of Chinese medicines. The total cost of Sinopharm's privatization proposal is about HK$15.45 billion.
Chinese Traditional Chinese Medicine (00570.HK) resumed trading this morning
Gelonghui, Feb. 22丨China Traditional Chinese Medicine (00570.HK) announced that the company's shares will resume trading at 9:00 a.m. today (22/2/2024).
China's traditional Chinese medicine announced that trading will resume on the morning of February 22
China Traditional Chinese Medicine (00570) announced that the company has applied to the Hong Kong Stock Exchange to resume share trading from 9:00 a.m. on February 22, 2024.
Chinese Traditional Chinese Medicine (00570) will resume trading at 9:00 a.m. on February 22
According to the Zhitong Finance App, China Traditional Chinese Medicine (00570) announced that it will resume trading at 9:00 a.m. on February 22, 2024.
Hong Kong Stock Announcement Nuggets | Privatization opens, the premium is 34.11%, see what is the opening discount?
Whether privatization is reasonable depends on whether the price is in line with the valuation level. With the current price premium of 34.11%, privatization of almost 1.05 pb (Pb caliber at the end of 2023) is OK.
China Traditional Chinese Medicine (00570.HK) was privatized by Sinopharm Group Gongyu at a premium of about 34.11% to resume trading tomorrow
Gelonghui, Feb. 21, 丨 China Traditional Chinese Medicine (00570.HK) announced that on February 9, 2024, the offender Sinopharm Group Gongyu Co., Ltd. requested the board of directors to submit proposals to the planned shareholders to privatize the company, which, if approved, would result in the cancellation of the stock's listing status on the Hong Kong Stock Exchange. The Board has reviewed the recommendations and agreed to present them to plan shareholders. The cancellation price of HK$4.6 per plan share cancelled in cash according to the plan is about 34.11% higher than the closing price of HK$3.43 per share reported on the Hong Kong Stock Exchange on the last trading day. The offeror is a family registered under the laws of the Cayman Islands
Trading of Chinese Traditional Chinese Medicine (00570) was suspended for a short time during the intraday period on February 8
China Traditional Chinese Medicine (00570) announced that the company's shares will be shortened from 9:18 a.m. on February 8, 2024...
Analysis
Price Target
No Data
